These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 6979442)

  • 21. The C4 and C2 but not C1 components of complement are responsible for the complement activation triggered by the Ra-reactive factor.
    Ji YH; Matsushita M; Okada H; Fujita T; Kawakami M
    J Immunol; 1988 Dec; 141(12):4271-5. PubMed ID: 3058802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
    Pearlstein E; Sorvillo J; Gigli I
    J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of complement by Schistosoma mansoni schistosomula: killing of parasites by the alternative pathway and requirement of IgG for classical pathway activation.
    Santoro F; Lachmann PJ; Capron A; Capron M
    J Immunol; 1979 Oct; 123(4):1551-7. PubMed ID: 113459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera.
    Clas F; Loos M
    Immunology; 1980 Aug; 40(4):547-56. PubMed ID: 6776034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation.
    Ahmed AE; Veitch J; Whaley K
    Immunology; 1990 Jun; 70(2):139-44. PubMed ID: 2373514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
    Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
    J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement, antigen-antibody complexes and immune complex disease.
    Naama JK; Niven IP; Zoma A; Mitchell WS; Whaley K
    J Clin Lab Immunol; 1985 Jun; 17(2):59-67. PubMed ID: 2931531
    [No Abstract]   [Full Text] [Related]  

  • 28. Immune complex mediated activation of the classical complement pathway.
    Borsos T
    Behring Inst Mitt; 1989 Jul; (84):93-101. PubMed ID: 2478118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes.
    Loos M
    Prog Allergy; 1982; 30():135-92. PubMed ID: 7041131
    [No Abstract]   [Full Text] [Related]  

  • 30. C1q binding and C1 activation by various isolated cellular membranes.
    Storrs SB; Kolb WP; Olson MS
    J Immunol; 1983 Jul; 131(1):416-22. PubMed ID: 6602834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
    Schifferli JA; Steiger G; Paccaud JP
    Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune complex modulation by plasma proteins. With special reference to the complement system and autoimmune diseases.
    Baatrup G
    Dan Med Bull; 1989 Oct; 36(5):443-63. PubMed ID: 2530063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway.
    Suankratay C; Zhang XH; Zhang Y; Lint TF; Gewurz H
    J Immunol; 1998 Mar; 160(6):3006-13. PubMed ID: 9510205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The complement system: physiology, disorders, and activity in the newborn infant.
    Johnston RB
    Mead Johnson Symp Perinat Dev Med; 1986; (24):7-12. PubMed ID: 2943950
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
    Kilgallon W; Amlot PL; Williams BD
    Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sheep serum complement sensitisation of sheep erythrocyte-rabbit antibody complexes for haemolysis by guinea-pig complement plus EDTA or Mg2+-EGTA.
    Jonas W; Stankiewicz M
    Arch Immunol Ther Exp (Warsz); 1986; 34(4):451-60. PubMed ID: 3099725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
    Füst G; Czink E; Minh D; Miszlay Z; Varga L; Hollán SR
    Clin Exp Immunol; 1985 Jun; 60(3):489-95. PubMed ID: 4017286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification.
    Harboe M; Garred P; Karlstrøm E; Lindstad JK; Stahl GL; Mollnes TE
    Mol Immunol; 2009 Dec; 47(2-3):373-80. PubMed ID: 19800125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
    Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
    Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.